文献速递物质与行为成瘾

认知偏差矫正对住院酒精戒断治疗成人早期复饮的影响:一项随机临床试验

Effect of Cognitive Bias Modification on Early Relapse Among Adults Undergoing Inpatient Alcohol Withdrawal Treatment: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2021-01-01

该随机临床试验在澳大利亚墨尔本4个住院戒断病房纳入300例中重度酒精使用障碍患者,比较连续4天认知偏差矫正(CBM)与假训练对出院后2周戒酒率的影响。结果显示CBM组戒酒率54.4%,对照组42.5%,差异11.9%(95%CI 0.04%-23.8%;P=0.04),支持CBM作为住院戒断期间辅助干预。

要点

  • CBM组出院后2周戒酒率54.4%,对照组42.5%,绝对差异11.9%(P=0.04)。
  • CBM安全易实施,仅需电脑和操纵杆,无需专业人员或培训。

核心结论

  • 在住院酒精戒断治疗期间提供CBM可提高出院后2周内的戒酒率。
  • CBM安全、易实施,可作为住院戒断期间的常规辅助干预以优化结局。

研究设计与样本

  • 随机临床试验,在澳大利亚墨尔本4个住院戒断病房筛选950例患者,最终300例随机分为CBM组(n=147)和假训练组(n=153)。
  • 纳入18至65岁、无神经系统疾病或创伤性脑损伤的中重度酒精使用障碍患者。
  • 干预为连续4天每日一次的CBM(旨在降低酒精接近偏向)或假训练;主要终点为出院后2周戒酒情况,采用时间线回溯访谈评估,随访研究者对分组盲法。

主要发现

  • CBM组戒酒率为54.4%(95%CI 46.0%-62.8%),对照组为42.5%(95%CI 34.3%-50.6%)。
  • 两组戒酒率差异为11.9%(95%CI 0.04%-23.8%;P=0.04)。
  • 7例患者(对照组3例,CBM组4例)因训练不适退出。

关键数值与推荐

  • 主要结局戒酒定义为出院后前14天内无任何酒精使用;复发定义为出院后前14天内任何酒精使用或失访。
  • 共300例随机患者中,248例完成干预,272例完成随访。

临床怎么用

  • CBM仅需电脑和操纵杆,无需专业人员或培训,可在住院戒断治疗期间作为辅助干预常规提供。
  • 干预为连续4天每日一次,可考虑用于中重度酒精使用障碍住院戒断患者以降低出院后早期复饮风险。

局限性

  • 随访仅至出院后2周,未评估更长期戒酒效果。
  • 部分患者因训练不适退出(共7例),可能影响依从性。
  • 最终随机样本300例来自单国4个戒断病房,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: More than half of patients with alcohol use disorder who receive inpatient withdrawal treatment relapse within weeks of discharge, hampering subsequent uptake and effectiveness of psychological and pharmacologic interventions. Cognitive bias modification (CBM) improves outcomes after alcohol rehabilitation, but the efficacy of delivering CBM during withdrawal treatment has not yet been established. OBJECTIVE: To test the hypothesis that CBM would increase the likelihood of abstaining from alcohol during the 2 weeks following discharge from inpatient withdrawal treatment. DESIGN, SETTING, AND PARTICIPANTS: In a randomized clinical trial, 950 patients in 4 inpatient withdrawal units in Melbourne, Australia, were screened for eligibility between June 4, 2017, and July 14, 2019, to receive CBM or sham treatment. Patients with moderate or severe alcohol use disorder aged 18 to 65 years who had no neurologic illness or traumatic brain injury were eligible. Two-week follow-up, conducted by researchers blinded to the participant's condition, was the primary end point. Both per-protocol and intention-to-treat analysis were conducted. INTERVENTIONS: Randomized to 4 consecutive daily sessions of CBM designed to reduce alcohol approach bias or sham training not designed to modify approach bias. MAIN OUTCOMES AND MEASURES: Primary outcome was abstinence assessed using a timeline followback interview. Participants were classified as abstinent (no alcohol use in the first 14 days following discharge) or relapsed (any alcohol use during the first 14 days following discharge or lost to follow-up). RESULTS: Of the 950 patients screened for eligibility, 338 did not meet inclusion criteria, 108 were discharged before being approached, and 192 refused. Of the 312 patients who consented (referred sample), 12 withdrew before being randomized. In the final population of 300 randomized patients (CBM, n = 147; sham, n = 153), 248 completed the intervention and 272 completed the follow-up. Of the 300 participants (173 [57.7%] men; mean [SD] age, 43.47 [10.43] years), 7 patients (3 controls, 4 CBM) withdrew after finding the training uncomfortable. Abstinence rates were 42.5% (95% CI, 34.3%-50.6%) in controls and 54.4% (95% CI, 46.0%-62.8%) in CBM participants, yielding an 11.9% (95% CI, 0.04%-23.8%; P = .04) difference in abstinence rates. In a per-protocol analysis including only those who completed 4 sessions of training and the follow-up, the difference in abstinence rate between groups was 17.0% (95% CI, 3.8%-30.2%; P = .008). CONCLUSIONS AND RELEVANCE: The findings of this clinical trial support the efficacy of CBM for treatment of alcohol use disorder. Being safe and easy to implement, requiring only a computer and joystick, and needing no specialist staff/training, CBM could be routinely offered as an adjunctive intervention during withdrawal treatment to optimize outcomes. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12617001241325.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Manning V, Garfield JBB, Staiger PK, et al. Effect of Cognitive Bias Modification on Early Relapse Among Adults Undergoing Inpatient Alcohol Withdrawal Treatment: A Randomized Clinical Trial. JAMA Psychiatry. 2021. PMID: 33146693. doi:10.1001/jamapsychiatry.2020.3446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。